Healius Ltd traded at 0.80 this Thursday February 12th, decreasing 0.06 or 6.43 percent since the previous trading session. Looking back, over the last four weeks, Healius lost 23.08 percent. Over the last 12 months, its price fell by 42.45 percent. Looking ahead, we forecast Healius Ltd to be priced at 0.88 by the end of this quarter and at 0.83 in one year, according to Trading Economics global macro models projections and analysts expectations.
Healius Limited is a healthcare company. The Company’s segments include Pathology, Imaging and Other. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment provides imaging services from standalone imaging sites, hospitals and medical centers. It has a network of pathology laboratories, collection centers and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. Its brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. Its Pathology operates 100 medical laboratories and 2,000 patient collection centers across metropolitan, regional and remote Australia. IQ Pathology is a specialized dermatopathology laboratory that provides comprehensive dermatopathology services Australia wide.